Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

206
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
206
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

124
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
124
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

427
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
427

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mapping inequalities in rheumatology care in Europe: the first edition of the EULAR RheumaFacts project.

Annals of the rheumatic diseases·2026
Same author

Which are the clinical characteristics that lead to the decision of primary or secondary usage of TNFi or IL-17i in patients with axial spondyloarthritis?: Real-world evidence from the RABBIT-SpA cohort.

EULAR rheumatology open·2026
Same author

Tocilizumab in German patients with RA: real-world evidence from the noninterventional studies ARATA and ICHIBAN.

EULAR rheumatology open·2026
Same author

Zeitschrift fur Rheumatologie·2026
Same author

Correction: Real-world sex differences in treatment persistence and reasons for discontinuation in psoriatic arthritis patients: results from the German RABBIT-SpA register.

Arthritis research & therapy·2026
Same author

The Global Rheumatology Workforce: Challenges and Considerations.

Rheumatic diseases clinics of North America·2026

Related Experiment Video

Updated: Jun 17, 2025

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
08:27

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Published on: September 20, 2018

7.5K

Rhekiss-The German Register for Child Wish and Pregnancies in Inflammatory Rheumatic Diseases.

Anja Strangfeld1,2, Yvette Meissner1, Anja Weiß1

  • 1Epidemiology and Health Services Research, German Rheumatism Research Centre Berlin, Berlin, Germany.

Pharmacoepidemiology and Drug Safety
|August 14, 2024
PubMed
Summary

The Rhekiss register collects crucial data on pregnancies in women with chronic inflammatory rheumatic diseases (IRD). This observational study provides insights into drug impacts and pregnancy outcomes for this patient group.

Keywords:
adverse pregnancy outcomes/pregnancy complicationsdrug treatment safetyinflammatory rheumatic diseasesobservational studypatient‐reported outcome measuresperinatal pharmacoepidemiologypregnancy

More Related Videos

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

58
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

97

Related Experiment Videos

Last Updated: Jun 17, 2025

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
08:27

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Published on: September 20, 2018

7.5K
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

58
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

97

Area of Science:

  • Pharmacoepidemiology
  • Rheumatology
  • Obstetrics

Background:

  • Pregnant and breastfeeding women are often excluded from clinical trials, necessitating observational studies for safety data.
  • Pregnancy registers are vital data sources for evaluating drug effects during pregnancy and on infant health.
  • Chronic inflammatory rheumatic diseases (IRD) pose unique challenges during pregnancy.

Purpose of the Study:

  • To establish a comprehensive data resource for assessing the impact of drug treatments on pregnancy, outcomes, and breastfed infants in women with IRDs.
  • To longitudinally investigate pregnancies in women with chronic IRDs through a nationwide register.

Main Methods:

  • The Rhekiss register is a nationwide, multicenter, longitudinal observational study.
  • Enrolment includes women aged 18+ with IRDs, either planning pregnancy or in the first half of pregnancy.
  • Prospective data collection via a web-based system and smartphone app, capturing maternal, clinical, treatment, and infant health information.

Main Results:

  • The Rhekiss register has enrolled 2013 individual patients.
  • Data from 1801 completed pregnancies are available for analysis.
  • The register uniformly assesses maternal and infant health, disease activity, and treatment exposures.

Conclusions:

  • Rhekiss is a comprehensive and complex register capable of addressing diverse research questions concerning pregnancy in women with chronic IRDs.
  • The collected data are essential for improving the management and safety of drug treatments during pregnancy for women with rheumatic diseases.